The Online Investor
OLI Premium
Contrarian Outlook
Stock Option Ideas
Preferred Stock Newsletter
ChartZero.com
MEI Pharma Inc (MEIP)

MEI Pharma is a clinical-stage pharmaceutical company focused on developing cancer therapies. Co.'s drug candidate pipeline includes voruciclib, an oral cyclin-dependent kinase 9 inhibitor, and ME-344, an intravenous small molecule mitochondrial inhibitor targeting the oxidative phosphorylation pathway.

Company Name:  MEI Pharma Inc
Website:  www.meipharma.com
Sector:  Drugs & Pharmaceuticals
Number of ETFs Holding MEIP:  3
Total Market Value Held by ETFs:  $1.16M
Total Market Capitalization:  $26.00M
% of Market Cap. Held by ETFs:  4.45%
March 29, 2024    6:13 AM Eastern


If the video does not load after a few moments, Upgrade to the Latest Flash Player.
Quotes delayed 20 minutes

Email EnvelopeFree MEIP Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Buy (3.00 out of 4)
27th percentile
(ranked lower than approx. 73% of all stocks covered)

Analysts' Target Price:
MEIP Stock Forecast

Based on Zacks ABR data;
powered by Xignite

MEI Pharma Inc (MEIP) Page | The Online Investor | www.TheOnlineInvestor.com | Copyright © 1998 - 2024, All Rights Reserved

Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes, powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.